Tamoxifen Use for the Management of Mania: a Review of Current Preclinical Evidence

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2014 Jan 21

PMID 24441937

Citations 5

Authors

Fernanda Armani

Monica Levy Andersen

Jose Carlos Fernandes Galduroz

Affiliations

Soon will be listed here.

Abstract

Rationale: Preliminary data on the efficacy of tamoxifen in reducing manic symptoms of bipolar disorder (BD) suggest that this agent may be a potential treatment for the management of this psychiatric disorder. However, the antimanic properties of tamoxifen have not been fully elucidated, hampering the development and/or use of mood-stabilising drugs that may share its same therapeutic mechanisms of action. Notably, we may gain a greater understanding of the neurobiological and therapeutic properties of tamoxifen by using suitable animal models of mania.

Objectives: Here, we review the preclinical studies that have evaluated the effects of tamoxifen to provide an overview of the current progress in our understanding of its antimanic actions, highlighting the critical role of protein kinase C (PKC) as a therapeutic target for the treatment of BD.

Conclusions: To date, this field has struggled to make significant progress, and the organisation of an explicit battery of tests is a valuable tool for assessing a number of prominent facets of BD, which may provide a greater understanding of the entire scope of this disease.

Citing Articles

The Use of Tamoxifen as a Potential Treatment for Bipolar Disorder.

Bagdadi N, Azab A, Shvartsur R Psychiatry Clin Psychopharmacol. 2024; 31(3):344-352.

PMID: 38765942 PMC: 11079652. DOI: 10.5152/pcp.2021.21817.

Suicidality and Illness Course Worsening in a Male Patient with Bipolar Disorder during Tamoxifen Treatment for ER+/HER2+ Breast Cancer.

Carmassi C, Pardini F, DellOste V, Cordone A, Pedrinelli V, Simoncini M Case Rep Psychiatry. 2021; 2021:5547649.

PMID: 33833890 PMC: 8012138. DOI: 10.1155/2021/5547649.

A Novel PKC Inhibitor Shows Promise for Amphetamine Use Disorders.

Newman A Neuropsychopharmacology. 2017; 42(10):1929-1930.

PMID: 28593999 PMC: 5561339. DOI: 10.1038/npp.2017.116.

Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.

Carpenter C, Sorenson R, Jin Y, Klossowski S, Cierpicki T, Gnegy M Bioorg Med Chem. 2016; 24(21):5495-5504.

PMID: 27647375 PMC: 5696786. DOI: 10.1016/j.bmc.2016.09.002.

Modeling mania in preclinical settings: A comprehensive review.

Sharma A, Fries G, Galvez J, Valvassori S, Soares J, Carvalho A Prog Neuropsychopharmacol Biol Psychiatry. 2015; 66:22-34.

PMID: 26545487 PMC: 4728043. DOI: 10.1016/j.pnpbp.2015.11.001.

References

Tang P, Roldan G, Brasher P, Fulton D, Roa W, Murtha A . A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol. 2006; 78(3):311-6. DOI: 10.1007/s11060-005-9104-y. View

Diazgranados N, Zarate Jr C . A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr Psychiatry Rep. 2008; 10(6):510-9. PMC: 2727597. DOI: 10.1007/s11920-008-0081-7. View

Lenox R, Watson D, Patel J, Ellis J . Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res. 1992; 570(1-2):333-40. DOI: 10.1016/0006-8993(92)90598-4. View

Aksoy E, Goldman M, Willems F . Protein kinase C epsilon: a new target to control inflammation and immune-mediated disorders. Int J Biochem Cell Biol. 2003; 36(2):183-8. DOI: 10.1016/s1357-2725(03)00210-3. View

Steketee J . Intra-ventral tegmental area administration of H7 delays, but does not prevent the development of cocaine-induced sensitization. Brain Res Bull. 1997; 43(6):565-71. DOI: 10.1016/s0361-9230(97)00089-0. View

Couldwell W, Hinton D, Surnock A, DeGiorgio C, Weiner L, Apuzzo M . Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res. 1996; 2(4):619-22. View

Walf A, Frye C . A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology. 2006; 31(6):1097-111. PMC: 3624621. DOI: 10.1038/sj.npp.1301067. View

Alda M, Hajek T, Calkin C, ODonovan C . Treatment of bipolar disorder: new perspectives. Ann Med. 2008; 41(3):186-96. DOI: 10.1080/07853890802409489. View

Kara N, Einat H . Rodent models for mania: practical approaches. Cell Tissue Res. 2013; 354(1):191-201. DOI: 10.1007/s00441-013-1594-x. View

10.

Garrido J, Godoy J, Alvarez A, Bronfman M, Inestrosa N . Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J. 2002; 16(14):1982-4. DOI: 10.1096/fj.02-0327fje. View

11.

Chen L, Hahn H, Wu G, Chen C, Liron T, Schechtman D . Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U S A. 2001; 98(20):11114-9. PMC: 58692. DOI: 10.1073/pnas.191369098. View

12.

Zhao Y, Wang L, Chaiswing L, Yen H, Oberley T, Lien Y . Tamoxifen protects against acute tumor necrosis factor alpha-induced cardiac injury via improving mitochondrial functions. Free Radic Biol Med. 2006; 40(7):1234-41. DOI: 10.1016/j.freeradbiomed.2005.11.009. View

13.

Churchill E, Budas G, Vallentin A, Koyanagi T, Mochly-Rosen D . PKC isozymes in chronic cardiac disease: possible therapeutic targets?. Annu Rev Pharmacol Toxicol. 2007; 48:569-99. DOI: 10.1146/annurev.pharmtox.48.121806.154902. View

14.

Ramakers G, Pasinelli P, Hens J, Gispen W, De Graan P . Protein kinase C in synaptic plasticity: changes in the in situ phosphorylation state of identified pre- and postsynaptic substrates. Prog Neuropsychopharmacol Biol Psychiatry. 1997; 21(3):455-86. DOI: 10.1016/s0278-5846(97)00013-4. View

15.

Nogues X . Protein kinase C, learning and memory: a circular determinism between physiology and behaviour. Prog Neuropsychopharmacol Biol Psychiatry. 1997; 21(3):507-29. DOI: 10.1016/s0278-5846(97)00015-8. View

16.

Chen G, Manji H, Hawver D, Wright C, Potter W . Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem. 1994; 63(6):2361-4. DOI: 10.1046/j.1471-4159.1994.63062361.x. View

17.

Cardoso C, Almeida L, Custodio J . 4-Hydroxytamoxifen is a potent inhibitor of the mitochondrial permeability transition. Mitochondrion. 2005; 1(6):485-95. DOI: 10.1016/s1567-7249(02)00034-x. View

18.

Machado-Vieira R, Salvadore G, Diazgranados N, Ibrahim L, Latov D, Wheeler-Castillo C . New therapeutic targets for mood disorders. ScientificWorldJournal. 2010; 10:713-26. PMC: 3035047. DOI: 10.1100/tsw.2010.65. View

19.

Barbini B, Bertelli S, Colombo C, Smeraldi E . Sleep loss, a possible factor in augmenting manic episode. Psychiatry Res. 1996; 65(2):121-5. DOI: 10.1016/s0165-1781(96)02909-5. View

20.

Rajkowska G . Cell pathology in bipolar disorder. Bipolar Disord. 2002; 4(2):105-16. DOI: 10.1034/j.1399-5618.2002.01149.x. View